|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.
|
|
 |
|
For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.
|
|
 |
|
In this presentation, Dr. Schlesinger demonstrates how to leverage a combination of measured and calculated molecular properties, bio-performance modeling, and a strategic understanding of the product TPP to identify a technology to enable exposure and an appropriate drug product design…..
|
|
 |
|
In this video, learn what the formulation and parameter targets are to optimize direct compression formulations, and how to accelerate development with BASF’s new all-in-one fit-for-purpose tableting solution.
|
|
|
|
|
|
|
|
|
Timothy Pas, PhD, and Vincent Levet, PhD, believe different solubility-enhancing technologies can be used by developers, and with different advantages and drawbacks, linked to payload, manufacturability, tolerability, and physical and chemical stability, effectively navigating solubility-enhancing solutions is multifaceted.
|
|
|
Emilio Cordova delves into how AI is transforming the drug discovery sector by enhancing predictability and efficiency and explains her company’s unique approach.
|
|
|
Lu Tian, PhD, says the complexity of LNP formulations demands diverse and integrated capabilities for development – incorporating lipids, oligonucleotides, small molecules, and sometimes antibodies or ligands, and thus it requires a cohesive approach.
|
|
|
Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.
|
|
|
Learn more about Stevanato Group and LGM Pharma in this exclusive Drug Development & Delivery annual Analytical Testing eBook.
|
|
|
|
|
|
|
|
|

Specializing in lentiviral and retroviral vectors, Genezen offers early-phase process development, GMP vector production, analytical testing services and assay development. Leveraging the expansive knowledge and experience of its team, Genezen accelerates cell and gene therapies to commercialization and helps deliver life-changing therapeutics to patients. Founded in 2014, the company strives to make viral vector production accessible to early-stage, growth-oriented companies and established industry leaders. Click here for more.
|
|
|
|
|
|
 |
|
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
|
|
 |
|
The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing. Since these devices….
|
|
|
|
|
|
Click image to watch Ligand’s latest Captisol video

|
|
 |
|
Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …
|
|
 |
|
Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.
Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared …
|
|
 |
|
Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …
|
|
 |
|
By: Jeffrey Tremain and Ania VanDyke, AbbVie Contract Manufacturing
Regulatory authorities now consider ophthalmic formulations designed for administration as eye drops to be drug-device combination products.The regulatory compliance requirements for such combination products are much more complex than those for …
|
|
|
|
|
Upcoming eNewsletter Features:
September 18 – Capsules
September 25 – Analytical Testing
|
|
|
|
|
|
|
|